Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $53 Price Target

Benzinga Newsdesk www.benzinga.com Negative 85.4%

Neg 85.4% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and maintains $53 price target.